This study demonstrates PGC2's enhanced drug release via electrical stimulation in gelatin cryogels, highlighting its biomedical applications.
Conductive cryogel is a new form of biomaterial that provides additional electrical properties, expanding its applications in biomedical engineering, particularly in tissue regeneration, such as neural and muscle tissues, and in drug-delivery systems. In this study, the gelatin cryogels (GCs) incorporating the conductive polymer PEDOT:PSS (PGC) at an optimal ratio (PGC2) could achieve suitable conductivity as an electrically responsive scaffold applied for controlled drug release. The characterization results demonstrated that PGC2 exhibited a well-defined porous structure (90-190 μm), a favorable water uptake capacity (2738.4%), degradability (26.1% degradation after 24 h), and reversible deformability upon compression, demonstrating its suitability for minimally invasive procedures via injection. The electron-transfer capability and higher conductivity of PGC2 were also confirmed by examining the electrochemical properties, which revealed a lower impedance (0.0174 MΩ) compared to nonconductive GC2 (0.0208 MΩ). Additionally, drug release tests revealed that drugs contained in PGC2 as electrically responsive scaffolds had a higher release response to electrical stimulation (ES) (23%) compared to the one without ES (7%). Cytocompatibility assays revealed that NIH-3T3 cells cocultured on PGC2 and those cultured with a PGC2 extraction solution exhibited cell viability above 70%, indicating nontoxicity, as confirmed by a WST-1 assay and a live/dead staining assay. Overall, PGC2 represents a promising biomaterial with injectability, conductivity, and cytocompatibility, offering potential applications in regenerative medicine, drug delivery, and bioelectronic scaffolding.
No takes yet. Share an insight, caveat, or question.
Chen et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: